Showing results (1111-1120 of 1,387) with videos related to
Sort By:
Pageof 139
Blood|April 1, 1994
A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicityP C Caron, J G Jurcic, A M Scott, et al.Cancer Research|June 19, 2001
Ny-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: correlation with tumor gradeT Kurashige, Y Noguchi, T Saika, et al.British Journal of Clinical Pharmacology|March 22, 2001
Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patientsP Tanswell, P Garin-Chesa, W J Rettig, et al.Annals of Neurology|July 1, 1994
Pyruvate dehydrogenase deficiency: molecular basis for intrafamilial heterogeneityT Fujii, R N Van Coster, S E Old, et al.Nature|February 6, 1986
Evolutionary relationships of human populations from an analysis of nuclear DNA polymorphismsJ S Wainscoat, A V Hill, A L Boyce, et al.Cancer Immunity|March 10, 2009
Sequential cancer immunotherapy: targeted activity of dimeric TNF and IL-8Stefan Bauer, Nicole Adrian, Uta Siebenborn, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 22, 2005
Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancerAli O Gure, Ramon Chua, Barbara Williamson, et al.Cancer Immunity|January 30, 2010
Cellular immune responses against CT7 (MAGE-C1) and humoral responses against other cancer-testis antigens in multiple myeloma patientsNikoletta Lendvai, Sacha Gnjatic, Erika Ritter, et al.Cancer Immunity|August 25, 2007
Expression of cancer-testis (CT) antigens in placentaAchim A Jungbluth, Wilson A Silva, Kristin Iversen, et al.Cancer Immunity|July 25, 2013
NY-ESO-1-specific immunological pressure and escape in a patient with metastatic melanomaLotta von Boehmer, Muriel Mattle, Peter Bode, et al.Pageof 139